Curis, Inc. (CRIS) Price Target Analysis
Analyst Rating: Buy
Based on 18 analystsNo Target Data
CRIS trades at Wall Street's consensus target of —.
Current Price$0.42
Average Target—
Low—
Median—
High—
Analyst Target Range
Forward P/E—
PEG Ratio—
Implied Growth-1345.6%
(Declining)
Analyst Spread—
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Consensus Scenario Assumptions
The base valuation assumes CRIS achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 18 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
CRIS Price Target Analysis
Updated June 22, 2026As of June 22, 2026, Curis, Inc. (CRIS) has a Wall Street consensus price target of N/A, based on estimates from 18 covering analysts. The company has a market capitalization of $82M.
Analyst price targets range from a low of N/A to a high of N/A.
The current analyst consensus rating is Buy, with 16 analysts rating the stock as a Buy or Strong Buy,2 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, CRIS trades at a trailing P/E of -0.7x. Analysts expect EPS to grow -1345.6% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside
+66.6%
Industry Consensus
Avg Forward P/E
65.8x
(High Premium)
Peers with Coverage
10 / 10
Active Analyst Tracking
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 TGTXTG Therapeutics, Inc. | $8.1B | $53.22 | $54.50 | +2.4% | Buy | 38.6x | 13 |
 KPTIKaryopharm Therapeutics Inc. | $77M | $9.02 | $14.17 | +57.1% | Buy | — | 20 |
 MGNXMacroGenics, Inc. | $263M | $4.13 | $6.00 | +45.3% | Buy | — | 22 |
 IMVTImmunovant, Inc. | $7.3B | $35.34 | $45.00 | +27.3% | Buy | — | 23 |
 PRTAProthena Corporation plc | $468M | $8.93 | $19.00 | +112.8% | Buy | 191.2x | 28 |
 PTCTPTC Therapeutics, Inc. | $6.6B | $78.98 | $95.83 | +21.3% | Buy | 89.1x | 26 |
 FATEFate Therapeutics, Inc. | $244M | $2.09 | $5.50 | +163.2% | Buy | — | 31 |
 AGENAgenus Inc. | $125M | $3.00 | $7.33 | +144.3% | Buy | 3.8x | 11 |
 INVAInnoviva, Inc. | $1.7B | $22.49 | $37.00 | +64.5% | Buy | 6.3x | 10 |
 RCUSArcus Biosciences, Inc. | $2.4B | $24.31 | $31.00 | +27.5% | Buy | — | 18 |
CRIS — Frequently Asked Questions
Quick answers to the most common questions about buying CRIS stock.
What is the CRIS stock price target for 2026?
The consensus price target for CRIS is $N/A, close to the current price of $0.421 (N/A% implied move). Based on 18 analyst estimates, the stock appears fairly valued near current levels.
Is CRIS a buy, sell, or hold?
CRIS has a consensus rating of "Buy" based on 18 Wall Street analysts. The rating breakdown is predominantly bullish, with 16 Buy/Strong Buy ratings. The consensus 12-month price target of $N/A implies N/A% upside from current levels.
Is CRIS stock overvalued or undervalued?
CRIS's current price is $0.421 with a consensus target of $N/A (N/A% implied move). Analyst estimates suggest the stock is fairly valued at current levels.
How high can CRIS stock go?
The most bullish Wall Street analyst has a price target of $N/A for CRIS, while the most conservative target is $N/A. The consensus of $N/A represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover CRIS stock?
CRIS is well covered by analysts, with 18 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 16 have Buy ratings, 2 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the CRIS stock forecast?
The 12-month CRIS stock forecast based on 18 Wall Street analysts shows a consensus price target of $N/A, with estimates ranging from $N/A (bear case) to $N/A (bull case). The median consensus rating is "Buy".
Should I buy CRIS stock?
CRIS appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $N/A target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do CRIS price targets vary so much?
CRIS analyst price targets range from $N/A to $N/A, a NaN% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $N/A consensus represents the middle ground.
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare